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Introduction
Zika virus (ZIKV) became a prominent international concern in 2015 when it caused a large epidemic in 
the Americas linked to thousands of  birth defects, miscarriages, and stillbirths, as well as cases of  Guil-
lain-Barre syndrome in several countries (1). These severe phenotypes are in contrast to the majority of  
infections that are asymptomatic or cause only a self-limited illness. ZIKV is only one example of  many 
expanding, emerging, or reemerging mosquito-borne flaviviruses (2). In locales where yellow fever vaccine 
is not routinely administered, sporadic outbreaks result in 100,000 severe cases, with tens of  thousands 
of  deaths each year (3), and dengue virus (DENV) continues to pose a threat to two-thirds of  the world’s 
population, with more than 300 million new infections every year (4). To successfully deal with emerging 
flaviviruses, multifaceted and coordinated response efforts are required. Central to these endeavors is a 
comprehensive knowledge of  human immune responses to these pathogens, which directly supports devel-
opment of  vital public health tools such as vaccines and diagnostics. Indeed, vaccination against yellow 
fever, tick-borne encephalitis, and Japanese encephalitis has demonstrated the potential public health ben-
efit of  developing effective vaccines against flaviviruses (4).
The recent Zika virus (ZIKV) epidemic in the Americas has revealed rare but serious manifestations 
of infection. ZIKV has emerged in regions endemic for dengue virus (DENV), a closely related 
mosquito-borne flavivirus. Cross-reactive antibodies confound studies of ZIKV epidemiology 
and pathogenesis. The immune responses to ZIKV may be different in people, depending on 
their DENV immune status. Here, we focus on the human B cell and antibody response to ZIKV 
as a primary flavivirus infection to define the properties of neutralizing and protective antibodies 
generated in the absence of preexisting immunity to DENV. The plasma antibody and memory 
B cell response is highly ZIKV type–specific, and ZIKV-neutralizing antibodies mainly target 
quaternary structure epitopes on the viral envelope. To map viral epitopes targeted by protective 
antibodies, we isolated 2 type-specific monoclonal antibodies (mAbs) from a ZIKV case. 
Both mAbs were strongly neutralizing in vitro and protective in vivo. The mAbs recognize distinct 
epitopes centered on domains I and II of the envelope protein. We also demonstrate that the 
epitopes of these mAbs define antigenic regions commonly targeted by plasma antibodies in 
individuals from endemic and nonendemic regions who have recovered from ZIKV infections.
ZIKV has an 11-kb positive-sense, single-stranded RNA genome, which encodes 7 nonstructural (NS) 
proteins and 3 structural proteins: capsid (C), premembrane (prM), and envelope (E) (1). Although other 
components of  the adaptive immune system such as T cells are likely important for long-term immunity (5, 
6), a large body of  work has supported a central role for neutralizing antibody (Ab) responses. E protein is 
the main target of  neutralizing and protective Abs elicited in people exposed to flavivirus infections or vac-
cines (7–14). The flavivirus E protein is a class II viral fusion protein that mediates attachment to cellular 
receptors and low-pH-triggered fusion within endosomes required for viral entry into cells. The E protein 
monomer contains 3 distinct domains, designated EDI, EDII, and EDIII (15). The surface of  the flavivirus 
virion is covered by 90 E protein homodimers, which are tightly packed to form a viral envelope with ico-
sahedral symmetry (16, 17). For DENV and West Nile virus, flaviviruses closely related to ZIKV, human 
neutralizing Abs often target complex or quaternary epitopes, with Ab binding footprints that include resi-
dues on multiple adjacent E monomers on the intact virion (18–21).
Particularly for the 4 DENV serotypes, studies have demonstrated that humans exposed to primary 
flavivirus infections develop type-specific neutralizing Abs and memory B cells (MBCs) that are strongly 
correlated with long-term protection from reinfection by the same virus (12, 22, 23). Understanding humor-
al immunity to ZIKV is complicated, in that most ZIKV transmission occurs in areas where DENV (and 
potentially other flaviviruses) are endemic, with DENV seroprevalence as high as 90% by early adulthood 
(24, 25). Ab cross-reactivity at the level of  binding and neutralization is a well-known phenomenon among 
flaviviruses in general and between DENV and ZIKV in particular, which can confound serologic assays 
(26–29). The impact of  Ab cross-reactivity on clinical outcomes for ZIKV infections in DENV-immune 
hosts (and vice versa) remains an active area of  investigation (30–32). Extensive cross-reactivity is expected 
given considerable conservation in the amino acid sequences of  DENV and ZIKV E (approximately 50%) 
(17, 33). Furthermore, B cell and Ab responses to a second DENV infection are skewed by preferential 
activation of  preexisting cross-reactive MBCs. Indeed, recent studies suggest that a similar phenomenon 
may occur when ZIKV infects a DENV-immune person (34–37). However, we (38) and others (35, 36) have 
observed that ZIKV type-specific Ab responses develop in humans even in the presence of  immunity to 
prior DENV infection.
Here, we focused on understanding the molecular determinants of  the human neutralizing Ab response 
to primary ZIKV infection. To date, most ZIKV infections have occurred in DENV-immune individu-
als, but as ZIKV becomes endemic throughout Latin America and the Caribbean, more individuals will 
experience ZIKV as their first flavivirus infection. To learn how ZIKV may affect immunity to subsequent 
flavivirus infection, or how secondary flavivirus infection could alter existing immunity to ZIKV, we must 
first understand the immune response to ZIKV in the absence of  other (particularly DENV) flavivirus expo-
sures. Additionally, understanding the properties and mechanisms underlying the induction of  neutralizing 
Abs in naive individuals is directly relevant to developing vaccines for use in flavivirus-naive populations 
living in countries with endemic DENV and ZIKV transmission.
Results
Human subjects with primary ZIKV. To understand the Ab response when ZIKV is a primary flavivirus infec-
tion, we identified 4 US residents that acquired ZIKV infection during foreign travel (Table 1). All infec-
tions were in Latin America from 2015 to 2016 and experienced uncomplicated, self-limited, symptomatic 
infections that resolved within 1 week. As we were mainly interested in the long-term MBC and plasma Ab 
responses, only late-convalescence blood samples collected 6 months or more after infection were analyzed. 
Subjects DT206 and DT244 reported positive ZIKV PCR testing during clinical evaluation following travel, 
and we detected anti-ZIKV IgM in plasma samples obtained from those 2 subjects within 12 weeks of  infec-
tion but not in the late-convalescence samples used in these studies (data not shown). All 4 subjects had 
strong type-specific neutralizing Ab responses to ZIKV (50% focus reduction neutralization test [FRNT50] 
titer range 1,845–5,267) (Table 1 and Figure 1C).
Human Ab responses to primary Zika. Plasma from all 4 ZIKV cases exhibited positive IgG binding in 
antigen-capture ELISA using ZIKV or a mix of  DENV1–4 virus as antigens, over a range of  plasma dilu-
tions (Figure 1A). The binding signal for DENV decayed more rapidly than for ZIKV, reaching assay limit 
of  detection between the 1:500 and 1:1000 dilution. IgG binding to ZIKV was readily detectable over back-
ground for all 4 primary ZIKV plasma at 1:1000, indicating higher IgG titers against ZIKV. All 4 plasma 
samples contained IgG Abs that also bound ZIKV recombinant E (ZIKV E80) and E domain I and III 
(ZVEDI and ZVEDIII) (Figure 1B). Consistent with the serologic diagnostic criteria used here to confirm 
ZIKV cases, the plasma from these 4 travelers strongly neutralized ZIKV by FRNTs and exhibited minimal 
to no cross-neutralization of  DENV serotypes 1–4 (Table 1 and Figure 1C).
Contribution to neutralization activity by distinct Ab subsets. Strongly neutralizing Ab responses to DENV 
often target E protein quaternary epitopes displayed on the virion but not on recombinantly expressed 
monomeric E protein (18–20). We tested whether plasma neutralizing Abs in people infected with ZIKV 
recognized simple or quaternary epitopes on E protein. A recombinantly expressed monomeric ecto-
domain of  ZIKV E protein (ZIKV E80) was purified, immobilized onto beads, and used to deplete all 
ZIKV E80–binding Abs from the plasma of  primary ZIKV cases. Confirmation ELISA demonstrat-
ed loss of  ZIKV E80 binding activity (Figure 2A), but retained IgG binding to intact virions (Figure 
2B), albeit at variably reduced levels compared with the undepleted specimens. Compared with control 
depleted plasma, neutralization activity of  ZIKV E80–depleted plasma was unaffected for DT172 and 
DT244, but exhibited a partial reduction in FRNT50 for DT168 and DT206 (Figure 2C and Table 2). 
To confirm that the majority of  ZIKV neutralization is attributable to Abs against quaternary epitopes, 
plasma from each of  the 4 primary ZIKV cases were depleted with ZIKV virus-like particles (VLPs), 
which present all conformational epitopes of  the intact virion. Marked loss of  neutralization activity was 
observed (Figure 2D and Table 2). Taken together, these results indicate that primary ZIKV infection 
elicits a complex Ab response that includes populations of  Abs that are cross-reactive but non-neutraliz-
ing to DENV, as well as ZIKV type-specific neutralizing Abs. Furthermore, ZIKV-neutralizing Abs target 
quaternary epitopes, though a minor fraction of  neutralizing activity is attributable to Abs that target 
epitopes on the E monomer in some individuals.
The MBC response to primary ZIKV infection. To assess the MBC repertoire in primary ZIKV infection, we 
immortalized MBCs (39) from DT168 and DT172. Screening supernatants of  polyclonal cultures of  sorted 
immortalized MBCs for IgG binding to ZIKV and DENV1–4 revealed the frequencies of  antigen-specific 
MBCs (Figure 3). This calculation was based on the assumption of  stochastic sampling during sorting and 
the average presence of  1 unique clone in the originating 50-cell polyclonal culture capable of  producing 
IgG that yielded a positive ELISA signal. Across 480 polyclonal cultures (24,000 MBC clones), 267 cul-
tures were ZIKV reactive. The vast majority of  these culture supernatants showed exclusive specificity for 
ZIKV (n = 222, 83%), and a minority were cross-reactive to ZIKV and DENV (n = 45, 17%) (Figure 3). For 
DT168, the frequency of  ZIKV-specific MBCs was 1.2% of  total MBCs, with 1% ZIKV type-specific and 
0.2% ZIKV/DENV cross-reactive. DT172 was similar, with 0.9% ZIKV-reactive MBCs, comprising 0.8% 
ZIKV type-specific and 0.1% ZIKV/DENV cross-reactive.
Potent ZIKV-specific neutralizing monoclonal Abs following primary ZIKV infection. To better understand the 
molecular determinants of  ZIKV neutralization, we sought to isolate neutralizing monoclonal Abs (mAbs) 
and use these as tools for more-detailed studies of  virion-Ab interactions. Using single-cell sorting, we 
established monoclonal MBC cultures from 10 polyclonal cultures with positive ZIKV ELISA binding 
signals for subject DT168 (Table 3). We recovered approximately 40% of  the single-cell cultures as prolif-
erating, IgG-producing cultures. Supernatants from monoclonal cultures were then screened for ZIKV-spe-
cific IgG. Half  of  the polyclonal cultures yielded ZIKV-reactive monoclonal cultures. Among monoclonal 
cultures from a given polyclonal progenitor culture, we found multiple positive wells. For some monoclonal 
cultures (e.g., E3, H10, and G11), all of  the positive wells exhibited an extremely narrow range of  values 
for ZIKV binding (as assessed by optical density [OD] in ELISA), suggesting clonality, which for E3 was 
confirmed by sequencing all 6 ZIKV-specific subclones. This is consistent with the assumption that 1 clone 
Table 1. Demographic and serologic characteristics of subjects
Place 
infected Time after infection YFV vaccine Symptoms
FRNT50
DENV 1 DENV2 DENV3 DENV4 ZIKV
DT168 Brazil 6 months Unknown F, R, C, HA, AR, GI <20 <20 28 <20 3,931
DT172 Colombia 6 months No F, R, C, AR <20 <20 <20 <20 5,267
DT206 Honduras 6 months No F, R, HA, AR <20 <20 <20 <20 5,048
DT244 Puerto Rico 6 months No R <20 <20 <20 <20 1,845
F, fever; R, rash; C, conjunctivitis; HA, headache; AR, arthritis/arthralgia; GI, nausea, vomiting, or diarrhea.
in the original polyclonal culture was responsible for the initial positive signal. For E4- and D1-derived 
clones, positive monoclonal wells fell into 2 categories of  OD values differing by more than 20%, each with 
very narrow (<10%) intragroup OD value range, suggesting 2 clones may have been present in the poly-
clonal culture. We confirmed this for D1 by sequencing 1 of  the 2 potential clones and found 2 identical 
subclones of  the G9E monoclonal culture. Taken together, these results support our assumption that, on 
average, 1 clone in the 50-cell polyclonal culture produces a positive signal, thus validating the calculation 
for estimating ZIKV-specific MBC frequencies as above. Occasionally, multiple reactive clones may exist in 
the polyclonal culture. This would be more likely to happen when the frequency of  antigen-specific MBCs 
is higher, and it would lead to potential underestimation of  the antigen-specific MBC frequency. ZIKV 
IgG–positive reactive supernatants were then screened for neutralization activity (Supplemental Figure 1; 
supplemental material available online with this article; https://doi.org/10.1172/jci.insight.124588DS1; 
and data not shown). Again, subclones with tight OD values exhibited near-identical neutralization values.
We then isolated RNA from monoclonal cultures producing the 2 most potent ZIKV-neutralizing mAbs 
(A9E and G9E) and assessed IgG isotype, heavy chain–light chain pairing, V gene usage, complementari-
ty-determining region 3 (CDR3) sequence, and somatic hypermutations (SHMs) by sequencing of  Ig heavy 
and light chain gene products (Table 4) as described previously (40). We recovered 2 distinct mAbs — both 
were IgG1, both used Ig-λ light chain, and exhibited a high level of  non-silent SHMs in their CDR regions 
compared with framework regions (FWRs) across IGH and IGL. The 2 mAbs were distinct in heavy chain 
V(D)J gene usage and CDR3 sequence. These unique mAb IGH and IGL sequences were inserted into 
IgG1/Ig-λ expression vectors, respectively, and produced in HEK-293F cells as described previously (40, 41).
Figure 1. Primary serologic response to ZIKV. (A) Plasma from 4 primary ZIKV cases (DT168, DT172, DT206, and DT244) were tested for IgG binding to 
ZIKV (top) and DENV (bottom) over the dilution series indicated on the x axis. (B) Primary ZIKV plasma and primary (DT001) and secondary (DT000) 
DENV plasma were tested for IgG binding to ZIKV recombinant E (ZIKV E80), DENV recombinant E (DENV E80), ZVEDI, and ZVEDIII. (C) Neutraliza-
tion assays were also performed for each primary ZIKV plasma as well as a secondary (2°) DENV control. NHS, naive human plasma (negative binding 
control for ELISA).
Binding dynamics and epitope mapping. Both the A9E and G9E human mAbs bound ZIKV virions in an 
antigen-capture ELISA, but did not bind to DENV4, which was tested as a representative DENV serotype 
(Figure 4A). This result agreed with the initial characterization of  the polyclonal cultures from which these 
mAbs were derived. Surprisingly, both mAbs bound to recombinant ZIKV E80, and A9E bound to ZVEDI 
(EC50 = 2,500 ng/ml), albeit at higher concentrations compared with ZIKV E80 (EC50 = 40 ng/ml). Neither 
mAb bound to ZVEDIII (Figure 4B). Both mAbs were unable to bind DENV1–4 when testing each serotype 
individually, confirming ZIKV specificity (Supplemental Figure 2). To approximate the location of  the epitope 
recognized by each mAb, competition assays were performed (hereafter referred to as blockade of  binding 
[BOB]). A panel of  6 flavivirus cross-reactive and 6 ZIKV-specific mAbs were competed with A9E and G9E 
in BOB assays. DENV-specific mAbs were used as a control to establish 100% binding. As a positive control, 
unlabeled A9E or G9E mAb was competed with itself  and showed a high level of  autoblockade (Figure 4C). 
None of  the DENV type–specific controls decreased the OD signal of  A9E or G9E binding compared with 
control. Most flavivirus cross-reactive mAbs and ZIKV-specific mAbs failed to appreciably reduce the binding 
of  A9E or G9E, with 2 notable exceptions. Both EDE1 mAbs C8 and C10 (42), which bind across domain 
II of  E molecules paired in a homodimer, showed partial blockade of  G9E. Additionally, ZKA190, a human 
ZIKV-specific mAb known to bind to the EDI–III linker and lateral ridge of  EDIII (43), strongly blocked A9E 
with an EC50 similar to that exhibited by A9E against itself. Neither of  these 2 mAbs exhibited BOB activity 
against the other (data not shown), indicating that the 2 mAbs target distinct, non-overlapping epitopes.
Both A9E and G9E strongly neutralized Asian and African lineages of  ZIKV (Figure 4, D and E, and 
Supplemental Figure 3), but exhibited no activity against any of  the 4 DENV serotypes, St. Louis encephalitis 
Figure 2. Antibodies against quaternary epitopes are the predominant mediators of ZIKV neutralization. (A) Depletion of ZIKV E80–binding IgG in pri-
mary ZIKV plasma was confirmed by direct antigen-coating ELISA comparing ZIKV E80–binding IgG in depleted (red bars) to MBP-control-depleted (white 
bars) or undepleted (black bars) plasma. Mean optical density values from flavivirus-uninfected plasma (background) are subtracted from each group. (B) 
IgG binding to ZIKV in depleted plasma was tested by antigen-capture ELISA. Mean optical density values from flavivirus-uninfected plasma (background) 
are subtracted from each group. (C) FRNT assays were performed for ZIKV E80–depleted plasma and controls using ZIKV H/PF/2013. (D) FRNT assays 
were performed for ZIKV VLP–depleted plasma and controls using ZIKVH/PF/2013.
virus, or yellow fever virus. A9E and G9E exhibited mean FRNT50 concentrations of  8.3 and 29 ng/ml across 
all ZIKV strains tested. Finally, to investigate the potential of  these mAbs to protect against ZIKV infection in 
vivo, we treated 5-week-old Ifnar–/– mice (44) with 200 μg of  A9E, G9E, or isotype control IgG by intraperito-
neal injection 1 day prior to subcutaneous foot pad infection with 1,000 focus-forming units (FFU) ZIKV (H/
PF/2013). Control mice lost weight and succumbed to infection by 8–10 days, whereas all mice that received 
A9E or G9E gained weight and did not succumb to infection (Figure 4, F and G).
Escape mutations and further epitope mapping. To investigate the determinants for neutralizing mAb bind-
ing in a biologically relevant model system, ZIKV (PRVABC59) was passaged under increasing concentra-
tions of  A9E and G9E mAbs on Vero cells. No escape virus that could tolerate increasing concentrations 
of  G9E was isolated, even when beginning the process with a concentration of  G9E as low as 20.6 ng/ml. 
In contrast, for A9E, an escape virus was isolated after 3 rounds of  passage that could be propagated in the 
presence of  35,800 ng/ml A9E mAb (approximately 780 × FRNT50). Viral isolates were plaque purified 
to generate clonal stocks. Two viral isolates were tested for binding by mAb and plasma (Figure 5A) and 
for neutralization escape (Figure 5B). Isolate nomenclature is as follows: passage 4 from experiment 1 = 
A9E ZV 4.1 and passage 3 from experiment 2 = A9E ZV 3.2. A9E lost binding to escape mutants, whereas 
binding was retained by G9E, 1M7, and ZKA190 as well as by all 4 primary ZIKV polyclonal plasma. A9E 
failed to neutralize both of  the isolated escape mutants compared with potent neutralization of  the wild-
type (WT) positive control. However, G9E and 2 polyclonal primary ZIKV-immune plasma neutralized 
A9E escape mutants similarly to WT virus. Mutant viruses were sequenced and aligned to WT, with 2 
mutations, one in EDIII (V364I) and the other in EDI (G128D), detected as depicted in Figure 5C.
To map the epitopes engaged by neutralizing human mAbs by a complementary approach, both A9E 
and G9E were epitope mapped using alanine scanning shotgun mutagenesis (Figure 5, D and E), as previ-
ously described (45, 46). This approach compares mAb binding to a library of  prM/E proteins with distinct 
point mutations to binding of  control mAbs that normalizes for target protein expression and folding. One 
critical amino acid that significantly reduced binding was detected for each mAb. For A9E, loss of  binding 
was observed with mutation of  E162, which is within EDI, proximal to the glycan at N154. This result is 
consistent with the A9E escape mutant containing alterations in EDI and the partial binding of  this mAb 
to ZVEDI. For G9E, mutation of  residue R252 resulted in loss of  G9E Fab binding.
Representation of  A9E and G9E in ZIKV-infected subjects. Based on escape mutations and alanine scanning 
mutagenesis, A9E and G9E recognize distinct epitopes contained on ZIKV E. To test whether the epitopes 
engaged by A9E and G9E are frequently targeted by polyclonal plasma Ab in natural ZIKV infection and 
whether DENV infection could elicit cross-reactive Abs that bind similar epitopes present on ZIKV, a set of  
DENV- and/or ZIKV-immune plasma were competed against each mAb in BOB assays. The sources of plas-
ma included US travelers, PCR- and serology-confirmed ZIKV cases from León, Nicaragua, and subjects from 
a Sri Lankan hospital-based cohort with PCR-confirmed DENV infection. The majority of DENV-immune 
plasma failed to block mAb binding to ZIKV at a level greater than 20% (Figure 6A). The samples collected 
from DENV-immune plasma that showed greater than 40% blockade were collected during early convales-
cence when cross-reactive Abs are higher (Supplemental Figure 4). Plasma specimens from ZIKV-infected indi-
viduals were further analyzed by dividing them into primary versus secondary flavivirus infection (Figure 6B) 
and there was no difference in the level of blockade between the 2 groups. Plasma from DT168 exhibited great-
er than 70% blockade for each mAb; this was the highest level of activity among the 4 primary ZIKV-immune 
traveler plasma as expected, given that both mAbs were derived from DT168 peripheral blood mononuclear 
cells (PBMCs) (Supplemental Figure 5). Interestingly, when testing multiple specimens from the same donor 
Table 2. Neutralization titers in Zika-immune plasma following ZIKV antigen depletion
Undepleted Control ZIKV E80 Undepleted Control ZIKV VLP
DT168 2,985 2,191 535 676 538 <50
DT172 992 1,572 964 1,023 1,787 70
DT206 2,884 2,473 413 1,513 2,742 94
DT244 630 538 617 717 1,218 73
Numbers are FRNT50 values expressed as the calculated plasma dilution factor.
at different times, the later specimen tended to have higher BOB activity. DT206 and DT244 exhibit negligible 
BOB against A9E early (even through FRNT50 titers are high), but begin to show blockade (~30%) by 6 months 
after infection (Supplemental Figure 5). This suggests that BOB activity of plasma may be affected by changes 
in the specificities represented in the Ab repertoire, not just the amount of IgG being produced. To further test 
this hypothesis, paired samples from ZIKV cases in Nicaragua were analyzed at 21 days and 6 months after 
infection and the trend for 8 out of 10 specimens was an increase in BOB at the later time. Taken together, these 
findings indicate that, following natural ZIKV infection, Ab responses targeting the same antigenic region of  
the potent ZIKV-specific neutralizing clones we isolated are maintained into late convalescence.
Discussion
This study shows that the polyclonal Ab response in ZIKV-infected individuals comprises a complex mixture 
of  Abs that recognize quaternary epitopes present on intact virions, and epitopes present on the recombinant 
ZIKV envelope protein monomer (simple epitopes). Furthermore, our data indicate that the majority of  neu-
tralizing activity in the 4 primary ZIKV plasma specimens is attributable to Abs that recognize quaternary 
epitopes. Recent studies with other flaviviruses, particularly the 4 DENV serotypes, have reached similar 
conclusions, suggesting that the importance of  Abs targeting complex structural epitopes is a generalizable 
feature of  the human Ab response to this genus of  viruses (18–21, 47, 48). However, we observed in 2 of  
the 4 subjects that Abs targeting simple epitopes also contributed to plasma neutralizing activity (Figure 
2C). Similarly, other studies have identified ZIKV-serotype-specific mAbs, which target simple epitopes on 
recombinant envelope proteins, particularly on EDIII, and neutralize the virus at variable potency (34, 36, 
49, 50). Recently, our group has also found that epitopes on EDI and EDIII are frequently targeted by 
ZIKV-specific Abs (27). In DENV, it is known that EDIII-directed Abs generally constitute a minor com-
ponent of  the human neutralizing Ab response (51). We hypothesize that the same is likely true for ZIKV, 
but this is yet to be formally demonstrated. Taken together, these findings emphasize the contribution and 
protective role of  quaternary-epitope Abs in ZIKV neutralization following primary infection.
To analyze humoral immunity in greater detail and elucidate the molecular determinants of  neutral-
ization, we examined the MBC population from 2 subjects, isolated 2 distinct potently neutralizing mAbs 
from one of  the subjects, mapped their key binding determinants, and assessed the representation of  these 
2 mAb specificities in a more general population. Approximately 1% ± 0.04% of  immortalized MBCs were 
ZIKV reactive. One caveat to this estimate is the transduction efficiency of  MBCs by 6XL, though this is 
accounted for by expressing frequency estimates as a function of  immortalized cells. Another caveat is the 
possibility according to the Poisson distribution that not every well will have exactly 50 cells dispensed and 
cells have grown equally. Although the latter is difficult to assess, we have found up to a 4% variance in 
Figure 3. Frequency of ZIKV-specific and cross-reactive MBCs. MBCs were transduced using the 6XL method and 
culture supernatants assessed for ZIKV- and DENV-binding IgG. Pie charts show the proportion of ZIKV-specific and 
cross-reactive wells for 2 donors with prior primary ZIKV infection. The table below delineates the raw numbers used to 
calculate the proportions shown in pie charts and the total frequency of ZIKV-reactive MBCs for each donor. ZIKV-TS, 
wells were designated ZIKV-type specific when IgG ELISA result for that well was positive for ZIKV and negative for 
DENV antigen. ZIKV-CR, ZIKV cross-reactive, wells IgG positive for both ZIKV and DENV antigen.
observed versus expected cell dispensing after sorting. Given these limitations, our frequency estimates are 
within the expected range for antigen-specific MBC responses to DENV (52) and ZIKV (53), suggesting 
adequate sampling of  the MBC pool. The presence of  replacement mutations in the FWRs and CDRs 
of  IGVH/L genes of  MBC clones from which A9E and G9E were derived suggested that these MBCs 
have undergone somatic mutation. In these clones, the CDRs contained more replacement mutations than 
the FWRs. This is consistent with the low tolerability of  FWR replacement mutations compared with 
CDR replacement mutations (54). This is because FWRs are essential to maintain variable-region struc-
tural integrity (55, 56) and positive selection of  clones (57). Interestingly, A9E exhibited a positive ratio 
of  replacement to neutral FWR mutations in IGHV akin to potent anti-HIV mAbs (58). Functionally, we 
found the vast majority of  antigen-specific MBC clones isolated from primary ZIKV cases to be ZIKV spe-
cific and not cross-reactive to DENV. Others have clearly shown that ZIKV infection in a DENV-immune 
host activates preexisting, cross-reactive MBC responses (34–36), which means the repertoire selected when 
ZIKV is a primary versus secondary flavivirus infection could be distinct and have consequences for virus 
control, clinical outcome, and transmission. Our results also raise the question of  how the minor popu-
lation of  DENV cross-reactive MBCs generated following primary ZIKV infection will contribute to the 
humoral response to subsequent DENV infection.
Identifying targets of  the long-lived neutralizing Ab response is a fundamental requirement for vac-
cine development, as these may guide further antigen design as well as assessment of  vaccine-induced 
immunity. For DENV (18–20, 47) and other flaviviruses (21, 48), it has been observed that strongly neu-
tralizing, type-specific Abs often target quaternary epitopes, and our data support the same conclusion for 
primary ZIKV-immune individuals (Figure 2D). Interestingly, the 2 potently neutralizing mAbs isolated in 
our study bound to recombinant ZIKV envelope protein monomer. Depletion experiments (Figure 2) are 
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E3 0.60 → 120 12 10% 6 0.32 ± 0.01 
(0.3–0.35)
1 2% (1/50) 1 (84%) (“A9E”): 6 
identical 
subclones
E4 0.54 → 180 89 49% 68 0.23 ± 0.03 
(0.20–0.30)
2 4% (2/50) 1 (51%) N.D.
F11 0.51 → 120 20 17% 0 – – – – N.D.
H10 0.49 → 120 53 44% 5 0.25 ± 0.01 
(0.25–0.27)
1 2% (1/50) 1 (58%) N.D.
D1 0.49 → 120 77 64% 13 0.34 ± 0.04 
(0.30–0.40)
2 4% (2/50) 2 (83%, 
53%)
1 of 2 clones 
sequenced 
(G9E)D
B3 0.46 → 120 18 15% 0 – – – – N.D.
D10 0.44 → 120 60 50% 0 – – – – N.D.
C3 0.42 → 120 52 43% 0 – – – – N.D.
G11 0.42 → 120 53 44% 9 0.19 ± 0.02 
(0.14–0.22)
1 2% (1/50) 1 (58%) N.D.
F9 0.42 → 120 26 22% 0 – – – – N.D.
Mean ± SD 
or Totals
0.48 ± 0.06 1260 460 37% 101 0.27 ± 0.06 7 2.8% 
(1.4/50)
6
AMean ± SD of OD for ZIKV-binding ELISA (background = 0.1–0.15). BEquals 1 if SD ≤ 10% of mean, equals 2 if SD > 10% of mean, confirmed by sequencing of 
D1 and E3 clones. CNumber positive is defined as ≥50% neutralization of ZIKV; percentage neutralization is presented in parentheses. DClone G9E with 83% 
neutralization was sequenced. “A9E” full name is DT168 (A)-E3-(A)-E9. “G9E” full name is DT168 (A)-D1-(G)-E9. N.D., not determined.
consistent with subject DT168 having a neutralizing Ab response against ZIKV that recogniz-
es both simple and complex structural epitopes. An expanded set of  mAbs from DT168 and 
other ZIKV cases is being isolated for comparative study. It is highly likely that mAbs against 
quaternary ZIKV epitopes will be isolated from DT168. Additionally, binding of  the ZIKV 
E monomer does not preclude that residues on adjacent E proteins be included in the mAb 
footprint nor that these potential residues be critical for the mechanism of  neutralization by 
A9E and G9E. Thus, binding experiments such as those performed here are an important part 
of  mAb characterization but are limited in that structure and function cannot be inferred from 
results. Therefore, additional work is needed to fully understand the properties of  these 2 mAbs 
as well as the primary Ab response to ZIKV in general.
We found that A9E and G9E recognize distinct epitopes based on lack of  competitive 
binding by each other and on different critical binding residues identified by complementary 
epitope mapping approaches. A9E binding was blocked by ZKA190, whose epitope spans the 
lateral ridge of  EDIII and residues in the EDI/EDIII linker region (43). EDI likely contains 
part of, but not the entire, A9E footprint based on ZKA190 competition and the weaker binding 
of  EDI versus ZIKV E80 exhibited by A9E. It was not possible to generate an escape mutant 
to G9E, perhaps because the footprint of  G9E includes at least one critical residue essential for 
viral fitness. G9E appears to bind residues primarily in EDII because mutagenesis revealed loss 
of  binding with R252A, and this mAb did not bind monomeric EDI or EDIII. Moreover, BOB 
by EDE1 Abs (C8 and C10) supports an epitope in EDII. Taken together, our data suggest that 
the epitopes of  these 2 Abs do not overlap. In fact, we have solved a high-resolution crystal 
structure for G9E and observed that the footprint of  this mAb spans the homodimer (Adams, 
unpublished observation).
Antigen-specific responses arise under the influence of  a variety of  host- and pathogen-spe-
cific features, which leads to certain responses being particular to an individual (private), while 
others are more broadly represented in populations (public). The latter would need to be true 
for tracking of  an antigen-specific response to be a useful tool for vaccine development. In 
general, plasma Abs from ZIKV-immune individuals (including those with and without prior 
DENV infection) competed with A9E and G9E for ZIKV virion binding. DENV-immune plas-
ma seldom blocked binding of  A9E and G9E to ZIKV, or it did so with substantially less effi-
ciency. Interestingly, ZIKV-immune plasma from later times (>1 month and typically 6 months 
after infection) exhibited a greater degree of  blocking activity. Overall neutralization titers typ-
ically peak and decline before 6 months, which suggests that this effect is not simply due to 
total amount of  IgG present in the plasma, but may involve ongoing shaping of  specificities 
maintained in the Ab repertoire for months following acute infection. Although these results 
do not prove that the exact epitope of  either mAb is widely targeted in people with ZIKV infec-
tion, they do indicate that the region of  E surrounding the A9E and G9E epitopes appears to 
be highly immunogenic in human ZIKV infection.
It is important to note that in vitro selection of  escape mutants is a tool for epitope map-
ping and does not indicate that these same escape mutants are likely to arise in nature. The 
experimental conditions used in the lab do not model natural infection; the immunologic pres-
sure exerted by a naturally infected host is unlikely to be entirely against a single epitope, a 
point recently illustrated by a ZIKV glycosylation mutant that confers escape to a specific mAb 
but not to polyclonal plasma (59). Additionally, flaviviruses are subject to purifying selection 
due to both mammalian and insect hosts in their life cycle (60).
The primary goal of  this work was to study the primary Ab response to ZIKV in detail, 
but we identified 2 ZIKV mAbs with potential for further development for therapeutic (43, 
46) or diagnostic (61) purposes. The FRNT50 values of  A9E (3–17 ng/ml) and G9E (20–38
ng/ml) are among the most potent reported for native human ZIKV mAbs. Multiple strains
of  ZIKV, representing African and Asian lineages, were effectively neutralized, consistent
with the idea that ZIKV exists as a single serotype (62, 63). Additionally, A9E and G9E both
fail to bind or neutralize DENV, and both protected against murine lethal ZIKV challenge in
vivo. Finally, these 2 mAbs appear to define epitopes that are consistently targets of  the Ab



























































































































































































































































































































































































human plasma from ZIKV-infected individuals. Additional experiments, including more detailed in vivo 
work to assess various timing and dose schedules and for breakthrough or persistent viremia, are being 
pursued to further explore the prophylactic and therapeutic potential of  the mAbs.
Because people exposed to primary DENV infections also develop Abs cross-reactive to heterolo-
gous DENV serotypes with the potential to enhance viral replication and disease during a secondary 
heterotypic DENV infection (64–66), potential enhancement of  ZIKV disease by cross-reactive Abs 
elicited by prior DENV infection was a major concern early in the recent ZIKV epidemic. However, the 
grounds for this hypothesis is limited to in vitro experiments (33, 36, 67–69) and mouse models (70), 
but has not borne out in nonhuman primate studies (31, 71) or epidemiologically in humans (30, 72). 
It is also plausible that ZIKV infection may elicit cross-reactive Abs that could later enhance a subse-
quent DENV infection (32, 36, 73). The mAbs we have identified here do not bind DENV, precluding 
the possibility of  causing Ab-dependent enhancement (ADE) of  DENV infection. Enhancement of  
ZIKV infection is a theoretical possibility, but very unlikely as there is no evidence of  ADE occurring 
in natural ZIKV infection of  humans. Additionally, in contrast to DENV, all ZIKV strains constitute a 
single serotype (62), and we have shown that A9E and G9E potently neutralize different ZIKV strains 
from the Asian and African lineages. We further show that A9E- and G9E-like ZIKV-specific binding is 
present in a substantial portion of  primary ZIKV cases and such activity increases over time. This sug-
gests a narrowing of  the repertoire towards ZIKV specificity typified by A9E- and G9E-like reactivity, 
indicating limited potential for DENV enhancement by Abs of  this type.
Figure 4. mAbs from primary ZIKV case exhibit potent ZIKV-specific neutralization and confer in vivo protection against lethal ZIKV challenge. (A) 
Antigen-capture ELISA for IgG binding was performed for 2 candidate ZIKV mAbs and 2 control mAbs (C10, ZIKV and DENV neutralizing; 2D22, DENV2 
neutralizing) against DENV4 (left) and ZIKV (right). (B) Binding to ZIKV E monomers and EDI and EDIII was assessed for each mAb. (C) Competition assays 
(BOB) with a panel of mAbs with known binding specificities was performed to localize the epitopes of A9E and G9E. (D and E) FRNT assays against a 
panel of ZIKV strains and related flaviviruses were performed for A9E (D) and G9E (E). (F and G) Four- to 6-week-old Ifnar–/– mice were treated with 200 
μg of indicated A9E, G9E, or polyclonal human IgG as a negative control on day –1 and challenged with 1,000 FFU of ZIKV (H/PF/2013). Weight loss (F) and 
mortality (G) were monitored for 14 days after infection. Results represent 6 to 7 mice per group combined from 2 independent experiments. Weights are 
shown as mean ± SEM and were censored upon the first death in the group. NA, not applicable.
In conclusion, this work provides a foundation for further definition of  the molecular determinants 
of  ZIKV neutralization and the durable humoral responses that will contribute to protection against 
infection. The tools and approaches used here will be useful in assessing Ab and MBC responses elicit-
ed by candidate ZIKV vaccines and the further study of  Ab responses elicited by sequential, heterolo-
gous flavivirus infection.
Methods
Human subjects and biospecimen collection 
UNC travelers. Plasma was collected from North Carolina residents with self-reported risk for or diagnosis of  
arbovirus infection through travel. Plasma samples were tested by virus-capture ELISA. DENV- or ZIKV-reac-
tive plasma was further characterized by neutralization assays on Vero cells to verify prior flavivirus infection. 
Figure 5. Epitope mapping of ZIKV-neutralizing mAb. (A–C) Escape mutants for A9E were generated from PRVABC59. (A) Binding of indicated mAb 
(left) and plasma (right) against A9E escape mutants from 2 independent experiments is shown. (B) Neutralization of 2 A9E escape mutants from 2 
independent experiments by indicated mAb (top) and plasma (bottom) is shown. (C) ZIKV E homodimer with escape mutations indicated. (D) Amino 
acid residues critical for A9E mAb and G9E Fab binding were determined by alanine scanning shotgun mutagenesis. Plots show the binding of A9E and 
G9E versus control mAbs. The data point in red corresponds to the alanine mutant that significantly reduces probe mAb binding compared with loading 
control mAbs. (E) Critical residues (green spheres) discovered in alanine mutagenesis mapping are represented on a 3-dimensional model from a ZIKV 
cryo-EM structure (PDB ID: 5IRE). The fusion loop of E domain II is in cyan, domain I is in red, domain II is in yellow, and domain III is in blue.
Plasma that neutralized one DENV serotype or ZIKV with minimal neutralizing activity against other viruses 
were defined as primary flavivirus infections (meaning that the FRNT50 for a single DENV serotype or ZIKV 
is at least 4-fold higher than any other virus tested). In our ZIKV cases, the travel history of the subject corrob-
orated the primary ZIKV immune status. Secondary flavivirus infections were defined by the highest 2 or more 
FRNT50 values with less than 4-fold separation. Existing plasma with known flavivirus neutralization profiles 
were used as controls in several experiments: primary (1°) DENV neutralized a single DENV serotype and not 
ZIKV; secondary (2°) DENV neutralized at least 2 DENV serotypes and not ZIKV.
Nicaraguan subjects. Patients presenting with fever, rash, or nonsuppurative conjunctivitis in León, Nica-
ragua, were recruited to a prospective cohort study, in which ZIKV cases were identified by reverse transcrip-
tion PCR (RT-PCR) on site and confirmed serologically at the University of  North Carolina (UNC). ZIKV 
cases were sampled by blood draw at presentation and at weeks 2, 3, 4, 8, 12, and 24 after symptom onset.
Sri Lankan subjects. During a DENV1 epidemic in Sri Lanka in 2014, suspected symptomatic DENV 
cases were enrolled for prospective sampling. Cases were confirmed by RT-PCR. All subjects were enrolled 
within 4 days of  symptom onset and a convalescent blood sample was obtained (ranging from 16–29 days 
after onset of  symptoms).
Viruses and cells
The MR766 and Dakar 41525 strains of  ZIKV were obtained from the World Reference Center for Emerg-
ing Viruses and Arboviruses (R. Tesh, University of  Texas Medical Branch, Galveston, Texas, USA) (74, 
75). ZIKV strains H/PF/2013 and PRVABC59 were provided by the US Centers for Disease Control and 
Prevention (76, 77). ZIKV/2012/PHL (Genbank: KU681082), ZIKV/2014/TH (Genbank: KU681081.3), 
and ZIKV/2015/Paraiba (Genbank: KX280026.1, PMID 27555311) were obtained from Stephen White-
head (National Institute of  Allergy and Infectious Diseases, NIH). DENV WHO reference strains DENV1 
West Pac 74, DENV2 S-16803, DENV3 CH54389, and DENV4 TVP-360 were initially obtained from 
Robert Putnak (Walter Reed Army Institute of  Research, Silver Spring, Maryland, USA). DENV2 NGC, 
DENV2/1974/Tonga (Genbank: AY744147.1), DENV3/1978/Slemen (Genbank: AY648961.1), and 
Figure 6. A9E and G9E epitope-binding IgGs are widely represented in polyclonal plasma following natural ZIKV 
infection. (A) Blockade of binding (BOB) against A9E and G9E was tested among plasma at a 1:20 dilution from ZIKV 
and DENV cases from the UNC Traveler’s study, Nicaragua, and Sri Lanka, as was done for mAbs in Figure 4C. (B) The 
ZIKV cases were subdivided into primary (1°) and secondary (2°) ZIKV (ZIKV infection in a DENV-immune host). (C) 
Paired plasma specimens at 1:10 dilution from symptomatic ZIKV cases in Nicaragua were analyzed by BOB at early 
(day 21 after symptom onset) versus late (6 months after symptom onset) convalescence. An unpaired Student’s t 
test was performed to determine differences in means between groups as indicated by bars. **P < 0.01; ***P < 0.001; 
****P < 0.0001. ns, not significant.
DENV4/1981/Dominica (Genbank: AF326573.1) were used in neutralization experiments and were 
obtained from Stephen Whitehead. To perform culture-based experiments and maintain virus stocks, 
C6/36 Aedes albopictus cells (ATCC CRL-1660) or Vero (Cercopithecus aethiops) cells (ATCC CCL-81) were 
used. C6/36 cells were grown at 32°C with 5% CO2 in MEM supplemented with 10% fetal bovine plasma, 
L-glutamine, nonessential amino acids, and HEPES buffer. Vero cells were grown at 37°C with 5% CO2 in
DMEM supplemented with 5% fetal bovine plasma and L-glutamine. Virus stocks were titrated on Vero cells 
by plaque assay or focus-forming assay. All studies were conducted under biosafety level 2 containment.
Human mAb generation and identification
From subject DT168, mAbs were generated as previously described using the 6XL method (39). Briefly, 
total cryopreserved PBMCs were thawed and MBCs isolated by magnetic purification for CD22+ B cells 
and flow cytometric sorting for CD19+CD27+IgM– class-switched MBCs. MBCs were transduced with 6XL 
retrovirus (encodes both Bcl-6 and Bcl-xL) and activated with CD40L-expressing cells and recombinant 
human interleukin 21 (IL-21), which together support proliferation and secretion of  Ab (78). Transduced 
cells were sorted by GFP expression (transduction marker) into polyclonal cultures at 50 GFP+ cells/well 
on 96-well plates using fluorescence-activated cell sorting on a BD FACSAria III using the “single cell 
sort mask” mode, which provides the highest possible accuracy (<4% variance) in dispensing cells. Super-
natants from polyclonal cultures were tested for the presence of  IgG targeting ZIKV by capture ELISA. 
ZIKV-specific supernatants were further screened for cross-reactivity to DENV in capture ELISA, and 
for ZIKV E80 binding in direct antigen-coating ELISA. Selected ZIKV-specific polyclonal cultures were 
single-cell sorted into monoclonal cultures on a BD FACSAria III, grown on CD40L and IL-21, and then 
screened as above after 4 weeks. ZIKV-specific monoclonal cultures were further qualitatively tested for 
neutralization of  ZIKV by incubation of  ZIKV with 30 μl of  culture supernatants prior to infection of  Vero 
cells and assessment of  neutralizing activity by microneutralization assay (Supplemental Figure 3).
From frozen cell pellets of  monoclonal cultures we isolated RNA, performed nested PCR for IGH 
and IGL genes, and sequenced using specific primers as described previously (40, 41). Sequences were 
input into IgBLAST (https://www.ncbi.nlm.nih.gov/igblast/) and compared to germline to determine 
variable heavy and light chain usage, V-(D)-J gene usage, SHMs, CDR3 sequence, and IgG subtype. 
Because sequencing of  both of  the potently neutralizing mAbs revealed IgG1 isotype and Ig-λ light 
chain usage, we then used previously described methods (40, 41) to clone IGH and IGL into human 
IgG1 (Genbank, FJ475055) and Igλ expression vectors (Genbank, FJ517647), respectively. Heavy and 
light chain vectors were verified by sequencing and cotransfected into HEK-293F cells and mAbs were 
produced as described previously (40, 41).
ELISA
Binding of  mAb or plasma IgG to DENV or ZIKV was measured by capture ELISA as described pre-
viously (20). Briefly, DENV or ZIKV virions were captured by the anti–E protein mouse mAb 4G2, 
blocked with 3% nonfat dry milk (LabScientific, Inc), and incubated with mAb or human plasma at 
indicated dilutions at 37°C for 1 hour, and binding was detected with an alkaline phosphatase–conjugat-
ed goat anti–human IgG secondary Ab (MilliporeSigma) and p-nitrophenyl phosphate substrate (Milli-
poreSigma). Absorbance at 405 nm (OD) was measured on an Epoch or Cytation3 plate reader system 
(Bio-Tek). ELISA assays to measure recombinant antigen binding (ZIKV E80, ZVEDI, and ZVEDIII) 
or used to confirm depletion were performed as above with the exception that 50 ng purified antigen was 
coated directly on the plate at 37°C for 1 hour.
ELISA data are reported as OD values that are the average of  technical replicates unless otherwise 
indicated. Naive human plasma (NHS) served as the negative control in ELISA assays. In depletion exper-
iments, the OD of  depleted sample is expressed as percentage of  control from the same plasma as indicat-
ed. For IgG binding to myelin basic protein–tagged (MBP-tagged) fusion proteins ZVEDI and ZVEDIII, 
the OD values reported are background subtracted for each plasma individually (OD ZIKV – OD MBP).
BOB assay
BOB was performed as described previously (79). Briefly, ZIKV was captured using 4G2 and plates were 
blocked with 3% nonfat dry milk as for ELISA. Serial dilutions of  plasma were added to plates in dupli-
cate and incubated at 37°C for 1 hour. After washing, 100 ng/well of  alkaline phosphatase–conjugated 
G9E or A9E was added, and plates were incubated at 37°C for 1 hour. p-Nitrophenyl phosphate substrate 
was added, and color changes were quantified by spectrophotometry. Percentages of  blockade of  binding 
were calculated as follows: (100 − [OD of  sample/optical density of  control]) × 100.
Neutralization assays
Neutralization titers were determined by 96-well microFRNT (38, 80). Serial dilutions of  mAb or plas-
ma were mixed with approximately 50–100 FFUs of  virus in DMEM with 2% FBS. The virus-Ab 
mixtures were incubated for 1 hour at 37°C and then transferred to a monolayer of  Vero cells for 
infection for 2 hours at 37°C. OptiMEM overlay media (Gibco, 31985) supplemented with 2% FBS, 
1% Anti-Anti, and 5 g (1%) carboxymethylcellulose (MilliporeSigma, C-5013) was added, and cultures 
were incubated for 40 hours (ZIKV), 48 hours (DENV2 and DENV4), or 52 hours (DENV1, DENV3). 
Cells were fixed with 70 μl of  4% paraformaldehyde (Thermo Fisher Scientific, 28908) for 30 minutes. 
Permeabilization buffer (100 μl) was added for 10 minutes followed by 100 μl of  blocking buffer (3% 
normal goat plasma, MilliporeSigma G-9023 in permeabilization buffer) and left overnight at 4°C. Fifty 
microliters of  a mixture of  primary Abs 4G2 and 2H2 (81) (ATCC, HB-114; 2H2 not used for ZIKV) 
was added to the plates and incubated for a 1 hour at 37°C. Cells were washed with a microplate washer 
(Bio-Tek, ELx405) followed by the addition of  50 μl of  1:1900 horseradish peroxidase–conjugated goat 
anti-mouse secondary Ab (KPL,074-1806) for 1 hour at 37°C. Foci were visualized with 60 μl of  True 
Blue (KPL, 5510-0030) and counted with a user-supervised automated counting program on ×2-mag-
nified images of  microwells obtained on a CTL ELISPOT reader. Two NHS controls on each plate 
defined 100% infection.
Ab depletions
ZIKV recombinant E protein was purified as described previously (82) and conjugated to HisPur 
Ni-NTA magnetic beads (Thermo Fisher Scientific) per manufacturer’s instructions. Control beads were 
incubated with an equal amount His-tagged human MBP (His-MBP). For depletion, plasma were dilut-
ed 1:20 and incubated with 30 μg ZIKV E80 or His-MBP control split over 2 rounds for 1 hour at 37°C 
per round. Depletion was confirmed by a ZIKV E80–binding ELISA. Plasma were also depleted of  all 
ZIKV binding Abs using ZIKV VLPs as previously described (83). ZIKV VLPs were provided by The 
Native Antigen Company and produced by transiently expressing ZIKV prM and E proteins in sus-
pension culture–adapted HEK-293 cells. Supernatants were cleared by centrifugation and concentrated 
by tangential flow filtration. The VLPs were purified by discontinuous sucrose gradient, ion exchange 
chromatography, and size exclusion chromatography, which also provided exchange of  buffers to storage 
buffer. Purified VLPs were stored in 10 mM sodium phosphate, 20 mM sodium citrate, 154 mM sodium 
chloride, pH 7.4 at –80°C until further use.
Escape mutant selection and sequence analysis
ZIKV-PRVABC59 was incubated for 1 hour at 37°C with various concentrations of  mAb at 2 times 
the FRNT50 for initial escape selection. The mAb concentration was increased every 3–6 passages up 
to a maximum concentration of  1,000 × FRNT50. Vero cell monolayers in 6-well tissue culture plates 
were infected with ZIKV-mAb mixture at a MOI of  0.01 for 2 hours at 37°C. Vero cells were washed 
3 times with PBS, and media with the same concentration of  selecting mAb were replaced. Cultures 
were incubated up to 96 hours and checked daily for cytopathic effects. Virus growth in the presence of  
Ab was monitored by quantitative RT-PCR and by immunofluorescent detection of  ZIKV antigens in 
cell monolayers. WT ZIKV-PRVABC59 was passaged in media alone alongside virus undergoing mAb 
selection. The E gene of  stock, WT passaged, and escape mutants were sequenced and aligned in Vector 
NTI. Mutations resulting in changes in predicted amino acids were visualized in topographical models 
using PyMOL.
Epitope mapping
Alanine scanning mutagenesis was carried out by Integral Molecular on an expression construct for ZIKV 
prM/E (strain ZikaSPH2015; UniProt accession Q05320). Residues were mutagenized to create a library of  
clones, each with an individual point mutant (46). Residues were changed to alanine (with alanine residues 
changed to serine). The resulting ZIKV prM/E alanine-scan library covered 100% of  target residues (672 of  672). 
Each mutation was confirmed by DNA sequencing, and clones were arrayed into 384-well plates, one 
mutant per well. Cells expressing each ZIKV E mutant were immunostained with the mAb to be mapped 
and control mAbs to normalize for protein expression levels. Mean cellular fluorescence was detected using 
an Intellicyt flow cytometer. If  no critical mutations were identified in the initial screen, mAb was converted 
to Fab and rescreened. Mutations within critical clones were identified as critical to the mAb epitope if  they 
did not support reactivity of  the mAb, but did support reactivity of  conformation-dependent control mAbs. 
This counter-screen strategy facilitates the exclusion of  Env mutants that are globally or locally misfolded or 
that have an expression defect (45). Validated critical residues represent amino acids whose side chains make 
the highest energetic contributions to the mAb-epitope interaction (84, 85).
Mouse protection experiments
Five-week-old male and female Ifnar1–/– mice (C57BL/6 background) received 200 μg of  A9E, G9E, or IgG1 
isotype control by intraperitoneal injection 1 day prior to infection with 1,000 FFU of  ZIKV (H/PF/2013) 
by subcutaneous footpad inoculation (44). Weight and lethality were monitored daily for 14 days.
Statistics
FRNT50 values were determined in neutralization assays by using the sigmoidal dose response (variable 
slope) equation of  Prism 6 (GraphPad Software). Maximum (100%) infection was defined by the foci counts 
in negative control wells (negative plasma or non-neutralizing mAb). FRNT50 values are the calculated titer 
at which maximum foci counts are reduced by 50%. Dilution curves for plasma Ab and mAb binding were 
generated using the same equation. Reported FRNT50 values were required to have an R
2 greater than 0.75, 
a Hill slope greater than 0.5, and an FRNT50 falling within the range of  the dilution series. Kaplan-Meier 
curves were used to establish survival differences in mouse challenge experiments. An unpaired, 2-tailed 
Student’s t test was performed to compare between groups of  plasma tested in BOB experiments.
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